SCHEMBL7089035

SCHEMBL7089035

COc1ccc(C(=O)C[N+](=O)[O-])c(Cl)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 4/20 0.51
HTT P42858 2/20 0.51
GAA P10253 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
RAB9A P51151 3/20 0.47
NPC1 O15118 2/20 0.47
CYP3A4 P08684 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C19 P33261 1/20 0.47
FLT1 P17948 2/20 0.47
FLT4 P35916 2/20 0.47
KDR P35968 2/20 0.47
JAK2 O60674 1/20 0.46
TYK2 P29597 1/20 0.46
ALDH1A1 P00352 5/20 0.45
MAPT P10636 3/20 0.44
HPGD P15428 2/20 0.44
LMNA P02545 1/20 0.44
RAF1 P04049 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7084833 0.82 TNKS (0.52) MAPK1HTTGAANPSR1RAB9A
SCHEMBL10912278 0.81 MEN1 (0.55) HTTNPSR1ALDH1A1MAPTLMNA
SCHEMBL7088352 0.80 SMN1; SMN2 (0.52) NPSR1RAB9AKDRALDH1A1MAPT
SCHEMBL7220888 0.80 MAPK1 (0.61) MAPK1CYP3A4FLT1FLT4KDR
SCHEMBL4477551 0.80 JAK2 (0.51) MAPK1HTTGAANPSR1RAB9A
SCHEMBL10746001 0.79 LMNA (0.50) MAPK1HTTGAANPSR1RAB9A
SCHEMBL1438230 0.78 GSK3B (0.54) MAPK1HTTGAANPSR1RAB9A
SCHEMBL9640865 0.78 OR51E2 (0.47) MAPK1HTTRAB9ANPC1CYP3A4
SCHEMBL31021004 0.77 HTT (0.51) MAPK1HTTNPSR1RAB9ANPC1
SCHEMBL7084753 0.77 KMT2A (0.44) MAPK1GAACYP3A4JAK2TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030171422-A1 New nitromethyl ketones, process for preparing them and compositions containing them MERCK PATENT GMBH (DE) 2003-09-11 US disclosed
US-6559185-B2 Nitromethyl ketone compounds having aldose reduction inhibiting properties and methods for their use MERCK PATENT GMBH (DE) 2003-05-06 US disclosed
US-20030069312-A1 Antidiabetic agents LARDY CLAUDE (FR) 2003-04-10 US disclosed
US-6043281-A ALDOSE REDUCTASE INHIBITORS; TREATMENT OR PREVENTION OF COMPLICATIONS OF DIABETES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2000-03-28 US disclosed
EP-0983226-A1 NEW NITROMETHYL KETONES, PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM MERCK PATENT GmbH (DE) 2000-03-08 EP disclosed
US-5932765-A REDUCTASE INHIBITORS MERCK PATENT GESELLSCHAFT MIT (DE) 1999-08-03 US disclosed
WO-1998052906-A1 NEW NITROMETHYL KETONES, PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM MERCK PATENT GMBH (DE) 1998-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069312-A1 Antidiabetic agents SLC5A1, SLC5A2, GPR119 MAPK1 1514/4885HTT 4499/4885GAA 231/4885
US-20030171422-A1 New nitromethyl ketones, process for preparing them and compositions containing them AKR1B1, AKR1A1, AKR1C1 MAPK1 1107/4885HTT 4742/4885GAA 998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.